Literature DB >> 25795508

The Emerging Potential of the Apelin-APJ System in Heart Failure.

Jonathan R Dalzell1, John P Rocchiccioli2, Robin A P Weir3, Colette E Jackson4, Neal Padmanabhan5, Roy S Gardner6, Mark C Petrie6, John J V McMurray2.   

Abstract

The apelin-APJ system is a novel neurohormonal pathway, with studies to date suggesting that it may be of pathophysiologic relevance in heart failure and may indeed be a viable therapeutic target in this syndrome. This interest is driven primarily by the demonstration of its vasodilator, inotropic, and aquaretic actions as well as its apparent antagonistic relationship with the renin-angiotensin system. However, its promise is heightened further by the observation that, unlike other and more established cardioprotective pathways, it appears to be down-regulated in heart failure, suggesting that augmentation of this axis may have a powerful effect on the heart failure syndrome. We review the literature regarding the apelin-APJ system in heart failure and suggest areas requiring further research.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APJ; Apelin; heart failure; neurohormone; pathophysiology

Mesh:

Substances:

Year:  2015        PMID: 25795508     DOI: 10.1016/j.cardfail.2015.03.007

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  18 in total

Review 1.  The apelinergic system: a perspective on challenges and opportunities in cardiovascular and metabolic disorders.

Authors:  Eric Marsault; Catherine Llorens-Cortes; Xavier Iturrioz; Hyung J Chun; Olivier Lesur; Gavin Y Oudit; Mannix Auger-Messier
Journal:  Ann N Y Acad Sci       Date:  2019-06-25       Impact factor: 5.691

Review 2.  Emerging role of angiogenesis in adaptive and maladaptive right ventricular remodeling in pulmonary hypertension.

Authors:  Andrea L Frump; Sébastien Bonnet; Vinicio A de Jesus Perez; Tim Lahm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-02       Impact factor: 5.464

3.  17β-Estradiol and estrogen receptor α protect right ventricular function in pulmonary hypertension via BMPR2 and apelin.

Authors:  Andrea L Frump; Marjorie Albrecht; Bakhtiyor Yakubov; Sandra Breuils-Bonnet; Valérie Nadeau; Eve Tremblay; Francois Potus; Junichi Omura; Todd Cook; Amanda Fisher; Brooke Rodriguez; R Dale Brown; Kurt R Stenmark; C Dustin Rubinstein; Kathy Krentz; Diana M Tabima; Rongbo Li; Xin Sun; Naomi C Chesler; Steeve Provencher; Sebastien Bonnet; Tim Lahm
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

4.  A First-in-Human Study of AMG 986, a Novel Apelin Receptor Agonist, in Healthy Subjects and Heart Failure Patients.

Authors:  Peter Winkle; Steven Goldsmith; Michael J Koren; Serge Lepage; Jennifer Hellawell; Ashit Trivedi; Kate Tsirtsonis; Siddique A Abbasi; Allegra Kaufman; Richard Troughton; Adriaan Voors; Jean-Sebastien Hulot; Erwan Donal; Navid Kazemi; Joel Neutel
Journal:  Cardiovasc Drugs Ther       Date:  2022-04-23       Impact factor: 3.727

5.  Therapeutic Benefit and Gene Network Regulation by Combined Gene Transfer of Apelin, FGF2, and SERCA2a into Ischemic Heart.

Authors:  Edith Renaud-Gabardos; Florence Tatin; Fransky Hantelys; Benoît Lebas; Denis Calise; Oksana Kunduzova; Bernard Masri; Françoise Pujol; Pierre Sicard; Philippe Valet; Jérôme Roncalli; Xavier Chaufour; Barbara Garmy-Susini; Angelo Parini; Anne-Catherine Prats
Journal:  Mol Ther       Date:  2017-11-16       Impact factor: 11.454

6.  Prognostic Value of Serum Apelin Level in Children with Heart Failure Secondary to Congenital Heart Disease.

Authors:  Doaa El Amrousy; Heba El-Mahdy
Journal:  Pediatr Cardiol       Date:  2018-04-09       Impact factor: 1.655

7.  The impact of apelin and relaxin plasma levels in masked hypertension and white coat hypertension.

Authors:  Elias Sanidas; Kostas Tsakalis; Dimitrios P Papadopoulos; Kanella Zerva; Maria Velliou; Despoina Perrea; Marina Mantzourani; Dimitrios Iliopoulos; John Barbetseas
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-07       Impact factor: 3.738

8.  The Effect of Omega-3 Fatty Acids on Serum Apelin Levels in Cardiovascular Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Akramsadat Mortazavi; Ebrahim Nematipoor; Mahmoud Djalali; Seyed Ali Keshavarz; Simin Samavat; Mahnaz Zarei; Mohammad Hassan Javanbakht
Journal:  Rep Biochem Mol Biol       Date:  2018-10

Review 9.  International Union of Basic and Clinical Pharmacology. CVII. Structure and Pharmacology of the Apelin Receptor with a Recommendation that Elabela/Toddler Is a Second Endogenous Peptide Ligand.

Authors:  Cai Read; Duuamene Nyimanu; Thomas L Williams; David J Huggins; Petra Sulentic; Robyn G C Macrae; Peiran Yang; Robert C Glen; Janet J Maguire; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

10.  Sarcolipin haploinsufficiency prevents dystrophic cardiomyopathy in mdx mice.

Authors:  Satvik Mareedu; Ronald Pachon; Jayapalraj Thilagavathi; Nadezhda Fefelova; Rekha Balakrishnan; Nandita Niranjan; Lai-Hua Xie; Gopal J Babu
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-11-20       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.